Novartis Shareholders Give Green Light To Sandoz Spinoff

Separation Of Standalone Generics And Biosimilars Firm Expected To Proceed On 4 October

 
• By Dave Wallace

At an extraordinary general meeting held earlier today, Novartis shareholders gave the go-ahead for the spinoff of the Sandoz generics and biosimilars business, paving the way for a formal separation on 4 October.

Traffic light on green
Novartis shareholders have given the go-ahead to spin off Sandoz • Source: Shutterstock

More from Strategy

More from Business